Apriori Bio receives US$50 million in strategic investment
Apriori Bio is a developer of artificial intelligence prediction virus mutation system. Based on its unique artificial intelligence platform, it infers all possible mutations of the virus, and develops antibodies or drugs that can resist rapidly mutating viruses, such as new coronavirus, influenza virus and human immunity. Defective virus. Recently, Flagship Pioneering announced the launch […]
Apriori Bio receives US$50 million in strategic investment Read More »